Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Johann S. de Bono, Ruth Riisnaes et al.|Cancer Discovery|2021Cited by 161
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Johann S. de Bono, Adam Sharp et al.|Nature|2023Cited by 119
Advanced Prostate Cancer with ATM Loss: PARP and ATR InhibitorsAntje Neeb, Johann S. de Bono, Nicolás Herranz et al.|European Urology|2020Cited by 118
Characterizing CDK12-Mutated Prostate CancersPasquale Rescigno, Johann S. de Bono, Bora Gürel et al.|Clinical Cancer Research|2020Cited by 100
B7-H3 as a Therapeutic Target in Advanced Prostate CancerChristina Guo, Johann S. de Bono, Ines Figueiredo et al.|European Urology|2022Cited by 90